Castle Creek Biosciences chair Jeff Aronin

Scoop: Af­ter pulling IPO am­bi­tions last De­cem­ber, Jeff Aron­in's Cas­tle Creek turns to pri­vate back­ers

Jeff Aronin’s cell and gene ther­a­py biotech Cas­tle Creek Bio­sciences has raised $112 mil­lion in eq­ui­ty, End­points News has learned.

The Ex­ton, PA, biotech se­cured the fi­nanc­ing from 54 in­vestors, ac­cord­ing to an SEC fil­ing dat­ed May 2. The late-stage start­up had last year con­sid­ered a $100 mil­lion Nas­daq de­but, but in a sign of the bear mar­ket that has plagued hun­dreds of new­ly mint­ed pub­lic biotechs, Cas­tle Creek pulled those am­bi­tions in the last few weeks of 2021.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.